Invesco
LUCD icon

Invesco’s Lucid Diagnostics LUCD Stock Holding History

Invesco’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$88.5K Buy
82,754
+44,828
+118% +$48.3K ﹤0.01% 3748
2026
Q1 		$43.6K Sell
37,926
-17
-0% -$22 ﹤0.01% 3704
2025
Q4 		$41.4K Buy
37,943
+592
+2% +$662 ﹤0.01% 3722
2025
Q3 		$37.7K Buy
37,351
+1,734
+5% +$1.89K ﹤0.01% 3759
2025
Q2 		$41K Buy
+35,617
New +$46K ﹤0.01% 3735
2022
Q1 		– Sell
-17,331
Closed -$93K – 4063
2021
Q4 		$93K Buy
+17,331
New +$141K ﹤0.01% 3913

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Invesco's LUCD Position: Q2 2026 in Review

Invesco increased its Lucid Diagnostics (LUCD) stake by 118% in Q2 2026, buying an estimated $48.3K and bringing the position to 82,754 shares worth $88.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3748.

Invesco first reported a position in LUCD in Q4 2021 and has held it in 6 quarters since. The position peaked at $93K in Q4 2021. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Invesco held 82,754 shares of Lucid Diagnostics worth $88.5K as of Q2 2026.
  • Invesco bought 44,828 Lucid Diagnostics shares in Q2 2026, an estimated $48.3K.
  • Lucid Diagnostics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3748 holding.
  • Invesco first reported a position in Lucid Diagnostics in Q4 2021 and has held it in 6 quarters since.
  • Invesco's Lucid Diagnostics position peaked at $93K in Q4 2021.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.